Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority

Allecra Therapeutics ("Allecra") announced today that the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract

Related Keywords

South Africa ,Norway ,United States ,United Kingdom ,France ,Switzerland ,America ,French ,American ,Patrick Velicitat ,Andreas Kranzusch ,Keith Kaye ,Beta Lactamases Esbls ,Linkedin ,Division Of Allergy ,Drug Administration ,Journal Of The American Medical Association ,Robert Wood Johnson Medical School Rutgers University ,European Union ,European Medicines Agency ,Allecra Therapeutics ,American Medical Association ,Extended Spectrum Beta Lactamases ,Central America ,South America ,Infectious Diseases ,Robert Wood Johnson Medical School ,Rutgers University ,Chief Medical Officer ,Qualified Infectious Disease Product ,Fast Track ,Andera Partners ,Delos Capital ,Xeraya Capital ,Allecra Therapeutics Gmbh ,Chief Financial Officer ,Allecra ,Herapeutics ,Ublishes ,Final ,Hase ,Tellium ,Data ,Lama ,Cefepime ,Enmetazobactam ,Criteria ,Superiority ,